MiReven receives further investment from MRCF

Two high profile R&D collaborations including one with Silence Therapeutics

29-Aug-2012 - MiReven, an Australian microRNA company commercialising discoveries from the Western Australian Institute for Medical Research (WAIMR) on the anti-cancer potential of miR-7, announced that it had received a further AU$500K investment from the Medical Research Commercialisation Fund (MRCF) due to ...

Recombination hotspot stacks the DNA deck in finding a new diabetes susceptibility gene

04-Nov-2010 - The autoimmune disease type 1 diabetes (T1D), also known as juvenile diabetes, is diagnosed in approximately 70,000 children worldwide per year. Genetics is increasingly being recognized as playing a significant role in susceptibility to the disorder, but outside a handful of genes, a clear ...